Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company’s late-stage investigational candidate ITCA 650 to Merck’s Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

Originally posted here:
Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Scroll to Top